for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Bio-Path Holdings Inc

BPTH.OQ

Latest Trade

7.33USD

Change

-0.30(-3.87%)

Volume

80,291

Today's Range

7.16

 - 

8.05

52 Week Range

1.63

 - 

73.52

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Bio-Path Announces $8 Mln Registered Direct Offering Priced At-The-Market

Nov 21 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH HOLDINGS ANNOUNCES $8.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.BIO PATH - ENTERED AGREEMENTS WITH INVESTORS FOR SALE OF 808,080 COMMON SHARES & WARRANTS TO BUY UP TO 606,060 COMMON SHARES AT $9.90/SHARE & WARRANT.BIO PATH - WARRANTS WILL HAVE EXERCISE PRICE OF $9.90 PER SHARE AND EXERCISE PERIOD COMMENCING IMMEDIATELY UPON ISSUANCE AND A TERM OF 5 YEARS.

Bio Path Holdings Q3 Loss Per Share $0.78

Nov 15 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.78.AS OF SEPTEMBER 30, 2019, COMPANY HAD CASH OF $15.4 MILLION, COMPARED TO $1.0 MILLION AT DECEMBER 31, 2018.BIO PATH HOLDINGS- EXPECT TO FILE IND APPLICATION FOR PHASE 1 STUDY OF BP1003 FOR TREATMENT OF SOLID TUMORS INCLUDING PANCREATIC CANCER IN 2020.

Bio-Path Updates Intellectual Property Portfolio With Addition Of Recently Issued Second Platform Technology Patent

Sept 25 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH UPDATES INTELLECTUAL PROPERTY PORTFOLIO WITH ADDITION OF RECENTLY ISSUED SECOND PLATFORM TECHNOLOGY PATENT.BIO PATH HOLDINGS INC - UNITED STATES PATENT AND TRADEMARK OFFICE HAS ISSUED A PATENT WITH CLAIMS RELATED TO DNABILIZE.

Bio-Path Holdings Reports Second Quarter 2019 Financial Results

Aug 15 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.87.AS OF JUNE 30, 2019, COMPANY HAD CASH OF $17.1 MILLION.

Bio Path Holdings Files For Stock Shelf Of Up To $125 Mln

May 16 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO PATH HOLDINGS FILES FOR STOCK SHELF OF UP TO $125 MILLION - SEC FILING.

Bio-Path Holdings Q1 Loss Per Share $0.89

May 16 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 LOSS PER SHARE $0.89.AS OF MARCH 31, 2019, COMPANY HAD CASH OF $19.3 MILLION, COMPARED TO $1.0 MILLION AT DECEMBER 31, 2018.

Bio-Path Holdings Reports Full Year 2018 Financial Results

March 20 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS.BIO PATH HOLDINGS INC - AS OF DECEMBER 31, 2018, COMPANY HAD CASH OF $1.0 MILLION, COMPARED TO $6.0 MILLION AT DECEMBER 31, 2017.BIO PATH HOLDINGS INC - ON TRACK TO SUBMIT OUR INVESTIGATIONAL NEW DRUG APPLICATION TO BEGIN A PHASE 1 STUDY OF OUR SECOND DRUG CANDIDATE, BP1002.

Bio-Path Announces Clinical Update To Interim Analysis Of Phase 2 Prexigebersen Trial In Acute Myeloid Leukemia

March 6 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH ANNOUNCES CLINICAL UPDATE TO INTERIM ANALYSIS OF PHASE 2 PREXIGEBERSEN TRIAL IN ACUTE MYELOID LEUKEMIA.BIO PATH HOLDINGS INC - INTERIM DATA UPDATE FROM PHASE 2 STUDY DEMONSTRATES MEANINGFUL CLINICAL IMPROVEMENT WITH EXCELLENT PATIENT SAFETY PROFILE.BIO PATH HOLDINGS INC - COMPANY PROVIDES CLINICAL DEVELOPMENT PLAN WITH PATHWAYS TO REGISTRATION.BIO PATH HOLDINGS INC - PATH INTENDS TO FILE FOR REGISTRATION OF BP1002 FOR TREATMENT OF VENETOCLAX RELAPSES IN BOTH CLL PATIENTS AND AML PATIENTS.

Bio-Path Announces Clinical Update To Interim Analysis Of Phase 2 Prexigebersen Trial In Acute Myeloid Leukemia

March 6 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH ANNOUNCES CLINICAL UPDATE TO INTERIM ANALYSIS OF PHASE 2 PREXIGEBERSEN TRIAL IN ACUTE MYELOID LEUKEMIA.BIO PATH HOLDINGS INC - INTERIM DATA UPDATE FROM PHASE 2 STUDY DEMONSTRATES MEANINGFUL CLINICAL IMPROVEMENT WITH EXCELLENT PATIENT SAFETY PROFILE.BIO PATH HOLDINGS INC - COMPANY PROVIDES CLINICAL DEVELOPMENT PLAN WITH PATHWAYS TO REGISTRATION.BIO PATH-INTENDS TO FILE FOR REGISTRATION OF BP1002 FOR TREATING VENETOCLAX RELAPSES IN BOTH CLL PATIENTS & AML PATIENTS .

Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering

Jan 18 (Reuters) - Bio Path Holdings Inc <BPTH.O>::BIO-PATH HOLDINGS, INC. ANNOUNCES $1.7 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET.ENTERED AGREEMENTS WITH INSTITUTIONAL INVESTORS FOR ISSUANCE AND SALE OF 648,302 SHARES OF COMMON STOCK AT $2.65/SHARE.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up